

[View this email in your browser](#)



VALIDATING DIAGNOSTICS TO
COMBAT ANTIMICROBIAL RESISTANCE
BY OPTIMISING ANTIBIOTIC USE

 WWW.VALUE-DX.EU

NEWSLETTER APRIL 2024

VALUE-Dx Closing Conference

VALUE-Dx officially ends on 30 September 2024, but until that time, project partners will continue to go to all lengths to generate ground-breaking and much needed insights into the value of diagnostics to improve antimicrobial prescription. These findings will be presented in a two-day Closing Conference in Valencia on 4 and 5 September 2024. [Continue reading here.](#)



AMR expert interview with Dr. Füsün Can



Learn about the importance of collaboration in combating AMR in our latest interview with Dr. Füsün Can. She is a medical doctor and professor from Koc University in Istanbul. Dr. Füsün shares how she and her multidisciplinary team tackle emerging infectious diseases across Turkey and how COVID-19 impacted their AMR research. [Read it here.](#)


the final steps

In January 2024, the recruitment targets for ADEQUATE-paediatric and PRUDENCE were reached. This means that the trials are entering a new phase, namely data cleaning, statistical and microbiological analysis of samples and health-economic modelling. [Continue reading here to discover more about the next steps.](#)



ESCMID Global 2024

[ESCMID](#) has been an important partner since the start of the VALUE-Dx project, and its yearly congresses, now rebranded into ESCMID Global, provide unique opportunities to share the VALUE-Dx achievements and results with the global medical community. Today is the last day of the congress and not only were we invited to participate in the European Networking Corner with [a video to present our main objectives, actions and achievements](#), VALUE-Dx also co-organised a well-attended symposium on the management of lower respiratory tract infections. ESCMID members will be able to watch the presentations soon. Keep an eye on our social media channels for an update regarding this!



New VALUE-Dx paper on EU pricing & funding policies for point-of-care diagnostics

diagnostics evidence, limited transferability methods from medicines to diagnostics, and the absence of price regulation for studied diagnostics. [Read more.](#)



Copyright © 2022 VALUE-Dx, All rights reserved.



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.

Our mailing address is:

value_dx@uantwerpen.be

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).